PAM
CYTO

PVG Asset Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

PVG Asset Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27
Closed -$37.5K – 73
2021
Q1 		$37.5K Buy
+27
New +$36.2K 0.12% 43

Other funds holding CYTO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

PVG Asset Management's CYTO Position: Q2 2021 in Review

PVG Asset Management sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2021, closing a stake of 27 shares — an estimated $37.5K sold.

PVG Asset Management first reported a position in CYTO in Q1 2021 and held it in 1 quarter. The position peaked at $37.5K in Q1 2021. 11 funds tracked by Wall St. Rank hold CYTO as of Q2 2021.

  • PVG Asset Management reported no remaining Altamira Therapeutics Ltd position as of Q2 2021 after selling out during the quarter.
  • PVG Asset Management sold 27 Altamira Therapeutics Ltd shares in Q2 2021, an estimated $37.5K.
  • PVG Asset Management first reported a position in Altamira Therapeutics Ltd in Q1 2021 and held it in 1 quarter.
  • PVG Asset Management's Altamira Therapeutics Ltd position peaked at $37.5K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2021.

Based on PVG Asset Management's 13F filing for Q2 2021, filed 17 Aug 2021.